Park Avenue Securities LLC lowered its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 9.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,601 shares of the company's stock after selling 6,789 shares during the quarter. Park Avenue Securities LLC's holdings in AstraZeneca were worth $4,877,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of AZN. Price T Rowe Associates Inc. MD lifted its holdings in shares of AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company's stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares in the last quarter. Swedbank AB acquired a new stake in AstraZeneca during the 1st quarter worth approximately $186,127,000. Manning & Napier Advisors LLC bought a new position in AstraZeneca in the second quarter valued at approximately $188,476,000. Hsbc Holdings PLC boosted its holdings in shares of AstraZeneca by 750.3% in the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company's stock valued at $100,523,000 after buying an additional 1,132,362 shares during the period. Finally, Farallon Capital Management LLC increased its position in shares of AstraZeneca by 65.1% during the second quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company's stock worth $187,934,000 after acquiring an additional 950,000 shares in the last quarter. Institutional investors own 20.35% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently issued reports on AZN. Barclays upgraded AstraZeneca to a "strong-buy" rating in a report on Monday, June 24th. TD Cowen lifted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a "hold" rating to a "sell" rating in a report on Friday, September 13th. Erste Group Bank upgraded AstraZeneca from a "hold" rating to a "buy" rating in a report on Wednesday, September 11th. Finally, Citigroup raised AstraZeneca to a "strong-buy" rating in a research report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, AstraZeneca has an average rating of "Buy" and an average price target of $89.75.
Get Our Latest Report on AstraZeneca
AstraZeneca Stock Performance
NASDAQ AZN traded down $0.46 on Friday, reaching $77.47. The stock had a trading volume of 5,186,806 shares, compared to its average volume of 5,192,397. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company has a market cap of $240.20 billion, a P/E ratio of 37.98, a price-to-earnings-growth ratio of 1.50 and a beta of 0.46. The firm has a fifty day moving average of $81.62 and a two-hundred day moving average of $77.37. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the firm posted $1.08 EPS. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.07 EPS for the current year.
AstraZeneca Cuts Dividend
The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were given a dividend of $0.49 per share. The ex-dividend date was Friday, August 9th. This represents a yield of 1.8%. AstraZeneca's dividend payout ratio is 48.04%.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
